Nature. 1995 Apr 6;374(6522):569-71.

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al.

Source

Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

Abstract

Inhibitors of the human immunodeficiency virus type 1 (HIV-1) protease have entered clinical study as potential therapeutic agents for HIV-1 infection. The clinical efficacy of HIV-1 reverse transcriptase inhibitors has been limited by the emergence of resistant viral variants. Similarly, variants expressing resistance to protease inhibitors have been derived in cell culture. We now report the characterization of resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 (formerly designated L-735,524). Five of these variants, isolated from four patients, exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors. This suggests that combination therapy with multiple protease inhibitors may not prevent loss of antiviral activity resulting from resistance selection. In addition, previous therapy with one compound may abrogate the benefit of subsequent treatment with a second inhibitor.

Comment in

Nature. 1995 Apr 6;374(6522):494.

PMID:: 7700387; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Clinical Overview - HIV InSite

Molecular Biology Databases

Stanford HIV RT and Protease Sequence Database

Supplemental Content

Save items

Related citations in PubMed

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. [J Virol. 1996]
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, et al. J Virol. 1996 Dec; 70(12):8270-6.
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. [AIDS. 1999]
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM, Winters MA, Lawrence J, Merigan TC. AIDS. 1999 Feb 25; 13(3):359-65.
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. [Proc Natl Acad Sci U S A. 1996]
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE, Gong YF, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, Alam M, Colonno RJ, Lin PF. Proc Natl Acad Sci U S A. 1996 Feb 20; 93(4):1648-53.
Review In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. [Adv Exp Med Biol. 1996]
Review In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds.
Emini EA, Schleif WA, Deutsch P, Condra JH. Adv Exp Med Biol. 1996; 394:327-31.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection. [Drugs. 2003]
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.

See reviews... See all...

Cited by over 100 PubMed Central articles

Mining the Protein Data Bank to Differentiate Error from Structural Variation in Clustered Static Structures: An Examination of HIV Protease. [Viruses. 2012]
Mining the Protein Data Bank to Differentiate Error from Structural Variation in Clustered Static Structures: An Examination of HIV Protease.
Venkatakrishnan B, Palii ML, Agbandje-McKenna M, McKenna R. Viruses. 2012 Mar; 4(3):348-62. Epub 2012 Mar 5.
HIV-1 Antiretroviral Drug Therapy. [Cold Spring Harb Perspect Med....]
HIV-1 Antiretroviral Drug Therapy.
Arts EJ, Hazuda DJ. Cold Spring Harb Perspect Med. 2012 Apr; 2(4):a007161.
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. [Retrovirology. 2012]
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
van Maarseveen NM, Andersson D, Lepšík M, Fun A, Schipper PJ, de Jong D, Boucher CA, Nijhuis M. Retrovirology. 2012 Apr 1; 9:29. Epub 2012 Apr 1.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
Nature. 1995 Apr 6 ;374(6522):569-71.

PubMed
Where are the diseases of yesteryear? DaCosta's syndrome, soldiers heart, the ef...
Where are the diseases of yesteryear? DaCosta's syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia--and the mitral valve prolapse syndrome.
Circulation. 1976 May ;53(5):749-51.

PubMed
[The glutaminergic system (II): the physiopathological, clinical and therapeutic...
[The glutaminergic system (II): the physiopathological, clinical and therapeutic aspects].
Med Clin (Barc). 1995 Mar 4 ;104(8):306-16.

PubMed
Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance...
Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process.
J Rheumatol. 1994 Dec ;21(12):2322-8.

PubMed
Obstetric complications as antecedents of schizophrenia: empirical effects of us...
Obstetric complications as antecedents of schizophrenia: empirical effects of using different obstetric complication scales.
J Psychiatr Res. 1994 Nov-Dec ;28(6):519-30.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Source

Abstract

Comment in

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by over 100 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information